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Introduction 
The purpose of this paper is to discuss the different goals of ‘drug treatment’ within 
a European context and the key implications for those planning or delivering health 
and social responses. 
 
Europe faces increasingly more diverse and complex drug problems. Heroin and 
synthetic opioids remained ‘a central issue’ but stimulants, new psychoactive 
substances, ‘misused medicines’ and problematic cannabis are all important 
(EMCDDA, 2016a). About two fifths of those entering specialised treatment for drug 
use disorders (DUDs) in Europe are opioid users, almost a third are cannabis users, 
about a fifth are stimulant users (cocaine or amphetamines) and around a tenth use 
‘other’ drugs. Europe needs to respond to a wider range of drug problems and 
related issues, including increasing numbers of patients with acute health issues 
presenting to emergency services as a result of the use of new psychoactive 
substances (EMCDDA, 2016b) and increased morbidity and mortality among 
prematurely ageing opioid users. 
 
Europe also has a broad and diverse range of services to treat DUDs (EMCDDA, 
2016a), with large variation between countries in drug trends and the treatment 
services provided. 
 
According to the European Drug Report 2017, the majority of treatment for DUDs in 
Europe is provided by specialist outpatient treatment centres (974 000 people were 
treated in this setting in 2015) (EMCDDA, 2017a). In addition, other healthcare 
services provide outpatient treatment for people with DUDs, mainly in the form of 
opioid substitution treatment (OST). This is provided by general practice surgeries in 
some countries, such as Germany and France, but in other countries, such as 
Slovenia and Finland, treatment for DUDs is provided by mental health services). 
‘Low-threshold’ services also provide treatment. In 2014, residential and inpatient 
treatment services treated about 116 800 people with DUDs. Prison-based 
treatment for DUDs was reported for 82 100 people (Figure 1). 
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Figure 1: Numbers receiving drug treatment in Europe in 2015, by setting 
 
Source: EMCDDA (2017a). 
 
Definitions of ‘drug treatment’ 
Although many EMCDDA publications use the terms ‘drug treatment’ and/or ‘harm 
reduction’ interventions, this report uses the term ‘treatment of drug use disorders’ 
in line with the International standards for the treatment of drug use disorders 
(UNODC and WHO, 2016). The rationale for this approach is to recognise from the 
outset that, in line with international evidence, an effective response to DUDs 
requires a coordinated and integrated system of treatment modalities and 
interventions provided by specialist and generic services in multiple settings to meet 
the diverse needs of different population groups affected by DUDs. 
 
Are treatment goals important? 
In short, evidence indicates that services that are goal oriented and those that 
ensure that service users have individualised treatment plans are associated with 
better outcomes. Supportive, goal-directed treatment for DUDs is related to greater 
service user participation and satisfaction with treatment, and better drug use 
outcomes at discharge (Moos and Moos, 1998). In relation to goals for people in 
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treatment for DUDs, an international meta-analysis reported that in-treatment 
performance monitoring of behaviour against goals was found to have significant 
positive effects on treatment outcomes — in particular, better drug use outcomes 
(Goodman et al., 2013). National and international clinical guidelines on the 
treatment of DUD normally stress the importance of the development of service 
user involvement in setting goals in the context of treatment or care plans (UNODC, 
2008). 
 
Definitions of terminology associated with treatment goals 
A number of key terms are associated with goals during treatment of DUD. 
 
Harm reduction 
The World Health Organization (2017) defines harm reduction as: ‘policies or 
programmes that focus directly on reducing the harm resulting from the use of 
alcohol or drugs without necessarily affecting the underlying drug use’. The EMCDDA 
(2010) states that: ‘harm reduction gives clear primacy to a public health perspective 
in which the imperative is to reduce immediate harms, and the question of long-
term abstinence from drug use is either unaddressed or left open’. A core principle 
of harm reduction is often a hierarchy of intervention goals with primary emphasis 
on reducing the health-related harms of continued drug use. Harm reduction is now 
part of the mainstream policy response to drug use in Europe (EMCDDA, 2010). 
Arguably, the European Union (EU) and many European drug treatment services 
have ‘led the way’ globally in championing harm reduction goals and strategies, 
including the implementation of needle exchange to prevent the spread of blood-
borne disease; indeed, ‘harm reduction’ has been called the ‘European way’ (IHRA, 
2010). 
 
Abstinence 
The term ‘abstinence’ means different things to different stakeholders. Abstinence 
can mean not using a problem or index substance, but it can also mean not using any 
drugs or alcohol. Twelve-step ‘mutual aid’ bodies equate ‘abstinence’ with not using 
the ‘problem substance’ or ‘being clean’ (Narcotics Anonymous, 2017). There is 
intense debate about whether those in OST should be viewed as being ‘abstinent’, 
with several authors and policy bodies recommending that those in OST are 
recognised as being abstinent from heroin (Betty Ford Institute Consensus Panel, 
2007) or in medically maintained or assisted abstinence: ‘formerly opioid-dependent 
individuals who take naltrexone, buprenorphine, or methadone as prescribed and 
are abstinent from alcohol and all other non-prescribed drugs would meet this 
definition of sobriety’ (UKDPC, 2008; White and Mojer-Torres, 2010). 
 
Reintegration 
The EMCDDA considers reintegration to depend on three social pillars: housing; 
education and training; and employment (EMCDDA, 2012). Although many EU 
Member States report a gap in the support aimed at addressing the psychological 
and other needs of people with DUDs, drug policies have begun to focus attention 
on reintegration and recovery (EMCDDA, 2012). Although the term ‘reintegration’ is 
not used consistently in EU countries, the EMCDDA recognises that reintegration is a 
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key aspect of recovery from drug dependence but it also acknowledges that other 
areas of life are equally important, including supportive social networks and an 
ability to live free from stigma and discrimination. The EMCDDA recommends that 
‘social re-integration includes all those activities that aim to develop human, social, 
economic and institutional capital and activities that promote social integration 
should be integral to treatment’ (EMCDDA, 2012). 
 
Recovery 
According to the UNODC (2014), the term ‘recovery’ has many and diverse 
meanings, but all involve improvements in quality of life. For example, the United 
Kingdom Drug Policy Commission defines recovery as: ‘voluntarily sustained control 
over substance use which maximises health and well-being and participation in the 
rights, roles and responsibilities of society’ (UKDPC, 2008). 
 
Internationally, ‘recovery’ or recovery management as a core component of the 
treatment of DUD is now widely advocated (Betty Ford Institute Consensus Panel, 
2007; Humphries and Lembke, 2013; UK Home Office, 2010; UNODC, 2014; CCSA, 
2015). The concept of recovery has its roots in both mental health and addiction. 
From the late 1980s to the 1990s the concept of recovery was incorporated into 
mental health policy in most western countries (Pilgrim and McCranie, 2013). In the 
context of mental health, recovery is often described as a personal journey or 
process that has three core principles: agency (a sense of control over one’s life), 
opportunity (having a life beyond illness, including being part of society) and hope 
(belief that one can have a fulfilled life and should not settle for less) 
(SLAM/SWLSTG, 2010). 
 
However, the term ‘recovery’ in the field of addiction is still surrounded by 
controversy. It was associated historically with the ‘12-step’ Alcoholics Anonymous 
mutual aid programme and with abstinence. The World Health Organization still 
defines recovery as ‘maintenance of abstinence from alcohol and/or other drug use 
by any means’ (WHO, 2017). 
 
Many authors advocate that abstinence alone is not recovery, and that recovery is a 
wider concept involving a process of both voluntary control of substance use plus 
working towards positive outcomes in a range of other recovery capital domains. 
Granfield and Cloud (2001) consider these domains to be social capital (family and 
group relationships); human capital (health and well-being, aspirations, educational 
achievements, etc.); physical capital (housing and money); and cultural capital 
(values, beliefs and attitudes, and the ability to fit into dominant social behaviours) 
(Figure 2). 
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Figure 2: Domains of recovery capital 
Source: ACMD (2013).  
 
Services that treat DUDs consider hope and optimism to be important concepts 
contributing to recovery. For example, according to recent Scottish guidance ‘the 
service user should be seen as capable of changing and supported to do so’ (COSLA 
and the Scottish Government, 2014). In addition, the United Nations Resolution 57/4 
stresses that countries should play a role in reducing the stigma, marginalisation and 
discrimination of drug users by promoting reintegration and recovery (UNODC, 
2014). 
 
A question of definition or paradigm? 
Are the terms discussed in this paper just words related to goals in the treatment of 
DUDs, or do they represent more? Arguably, the terms ‘abstinence’, ‘harm 
reduction’, ‘reintegration’ and ‘recovery’ are focal points of intense cultural 
meaning. To some, the terms ‘harm reduction’ and ‘recovery’ in particular represent 
paradigms with fundamentally different models and aspirations of treatment and 
interventions for DUDs and have been the subject of debate and disagreement 
(White, 2007; EMCDDA, 2010; McKeganey, 2012). 
 
What are the goals can of treatment for DUDs and how do they differ across 
Europe? 
‘Top-line’ descriptions of each nation’s treatment provision for DUDs indicate that all 
EU countries provide ‘harm reduction and treatment interventions’; therefore, a 
range of treatment goals appear to be present to a greater or lesser extent in all EU 
countries (EMCDDA, 2017b). However, the balance of treatment modalities varies 
between countries, and these broad descriptions mask the complex development of 
national and local systems to treat DUDs and the resulting ‘dominant’ goals. 
 
 8
Factors influencing the goals of treatment of DUDs across Europe 
Different types or modalities of DUD treatment have different goals. In-patient and 
residential services tend to be abstinence oriented. The latter also tend to have a 
focus on reintegration and recovery goals (for example, Belgium and Germany 
describe their residential rehabilitation services as having explicit goals around 
employment, housing and reintegration) (EMCDDA, 2014a). Interventions that are 
‘low threshold’ and outreach services, such as needle exchange, extended brief 
interventions and drug consumption rooms in Germany, the Netherlands and 
Switzerland, have the stated goals of reducing acute harm and attracting people into 
treatment (EMCDDA, 2010). 
 
The type, nature and severity of DUDs may have an influence on goals. At an 
individual level, goals may change over the course of a journey through a DUD. In 
some countries, goals may vary according to the nature of drug problems may 
influence goals; for example, in the Czech Republic, treatment for 
methamphetamine DUD features mental health and residential treatment focused 
on improving mental health, abstinence and reintegration, and community-based 
interventions to reduce acute harm are also available (EMCDDA, 2014b). Some new 
psychoactive substances are more likely to cause acute health episodes (EMCDDA, 
2016b) than ‘dependence’, and treatment is therefore aimed at reducing acute 
health harm. 
 
Treatment goals can also be influenced by trends in the problems associated with 
drug use. For example, human immunodeficiency virus/acquired immunodeficiency 
syndrome (HIV/AIDS) was identified among people who injected drugs from 1985, 
and this led to attention being focused on reducing the harm associated with 
injecting drug use (EMCDDA, 2010). Similarly, in the United Kingdom, the realisation 
in the 1990s of the high level of drug-driven acquisitive crime led, in 2001, to a 
significant expansion in OST with the goal of reducing crime, with an initial emphasis 
on retaining drug users in treatment (Audit Commission, 2004). 
 
Goals also vary according to the target service user group; for example, for those in 
‘safety-critical’ employment, such as doctors, train drivers and members of the 
armed forces, abstinence goals are often a condition of treatment and employment. 
 
The ‘favoured’ approach in a locality or the historical dominance of a particular 
modality can influence the treatment options made available to different groups; for 
example, the type of cannabis treatment provided in different European countries is 
influenced by the dominant therapeutic approaches within countries (EMCDDA, 
2015a). 
 
The professional, cultural or religious background of those establishing and providing 
treatment for DUDs may also affect goals. For example, addiction psychiatrists tend 
to focus on the goals of overcoming dependence and improved mental and physical 
health outcomes, whereas a Christian rehabilitation unit is likely to take a more 
‘holistic’ focus, including an emphasis abstinence and spirituality. The amount and 
source (public, private or health insurance) of funding for the treatment of DUDs, the 
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associated priority drivers and expectations of outcomes can all influence the 
dominant goals in a locality. 
 
The perspective of different groups of ‘experts by experience’ or people who have 
used drugs have influenced goals. These perspectives are diverse and range from 
those involved in ‘12-step’ abstinence-based residential rehabilitation and 
community ‘mutual aid’ to aid recovery (Narcotics Anonymous, 2017) to community 
harm reduction advocates (EMCDDA, 2010). 
 
Political influences and changes in countries can result in changes in treatment goals. 
For example, countries that were previously part of the Soviet Union no longer insist 
on compulsory treatment for DUDs that is focused on abstinence (Latypov, 2011). 
 
General trends in healthcare can impact on goals for the treatment DUD. The trend 
in mental healthcare in some European countries, from inpatient psychiatric care to 
outpatient models of care, with a focus on self-management and recovery, is an 
example. 
 
It is worth noting that, although all countries now provide OST, the goals of OST are 
rarely recorded in national reports. However, some countries specifically state that 
OST programmes are designed to achieve ‘wider goals’. 
 
National reports (EMCDDA, 2015b) of systems of treatment for DUDs, including links 
with primary health services and mental health services, also describe goals to 
improve health (e.g. testing and treatment of blood-borne viruses in the United 
Kingdom). Similarly, countries that report integrated systems involving housing and 
employment have a focus on these outcome domains. For example, in Finland there 
are ‘income-related activities, living and employment assistance to facilitate 
treatment and recovery’ and Hungary reports ‘specialist supported housing aimed at 
aiding reintegration’. 
 
Are treatment goals mutually exclusive or interrelated, or are they the same man 
wearing a different hat? 
A ‘hierarchy of goals’ has been recognised as important in the treatment of DUDs for 
many years (ACMD, 1988), from reducing immediate harms caused by active drug 
use to the goal of abstinence from the problem substance. Some authors have 
argued that abstinence-oriented interventions therefore fall within the hierarchy of 
harm reduction (EMCDDA, 2010). Similarly, authors who are recovery oriented 
describe the need for initial interventions in a recovery journey to focus on 
preventing immediate harm (NTA, 2012). Therefore, harm reduction goals can be 
seen as intermediate steps on ‘a road to recovery’. Similarly, interventions that may 
be called ‘reintegration’ (e.g. facilitated access to education or training in some 
European countries) may be called ‘recovery’ interventions in others. These concepts 
are clearly related and overlapping, but if a system has a dominant focus on ‘harm 
reduction’ or ‘recovery’, can this create negative unintended consequences? 
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Treatment goals for opioid users and OST: a matter for debate? 
It is possible that the service user group for which the question of goals is the subject 
of most current debate is that of opioid users, particularly those with long drug-using 
careers, high levels of morbidity and poor reintegration, especially those in OST. 
 
There is a significant body of evidence showing that the treatment service itself, as 
well as its management, organisation, staffing and culture, has a significant impact 
on service user outcomes, even when services provide the same evidence-based 
interventions such as OST (Bell et al., 1995; Moos and Moos, 1998). However, are 
there real differences between how the ‘recovery’ and ‘harm reduction’ paradigms 
are operationalised in OST services, resulting in significant cultural differences and 
outcomes? 
 
A harm reduction orientation in OST may be wholly appropriate to reduce risk from 
continued drug use and promote engagement and retention. However, a lack of 
focus on longer-term drug use goals or wider goals may, arguably, create 
‘destination-free’ OST and prevent service users from overcoming dependence 
and/or achieving goals in other domains. Put differently, a short-term focus on 
meeting acute needs (through substitute medication) may not provide a longer-term 
or extensive model of care that supports lifestyle change to ameliorate the long-
term health condition of opioid dependence. The welcome addition of a focus on 
reintegration and wider recovery goals, particularly after the initial stages of OST, 
may help service users achieve a better quality of life and a wider range of outcome 
goals — irrespective of whether or not they remain in OST. 
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A case study  
In 2012, in England, drug treatment services were asked to measure their service against 
new guidance on recovery-oriented drug treatment (RODT); I was the director of an NHS 
service providing DUD treatment for over 5 000 heroin users a year. The dominant culture in 
the service was one of ‘reducing harm’. The service had good outcomes in terms of reduced 
opioid use and retention in treatment, but many service users dropped out after a year or 
so, and very few opioid users detoxified and sustained abstinence or gained employment. 
Initially, the staff reported that they already provided a service that promoted reintegration 
and recovery. In some ways, they were correct. We comprehensively assessed service users 
and provided needle exchange and hepatitis B virus vaccinations. Service users had care 
plans, received OST and were offered psychosocial interventions and liaison with health and 
social welfare services. Narcotics Anonymous ran weekly evening groups in the services. 
However, when we reviewed our service against the RODT audit criteria, our culture and 
interventions were not fully recovery oriented. Our focus was getting people stable on OST, 
retaining them and preventing harm, but we lacked focus on long-term goals and other 
domains. We did not assess services user assets as well as problems. We did carry out health 
screening, hepatitis B virus vaccinations and referred for blood-borne viruses and mental 
health treatment but did not have health improvement plans to help people stop smoking, 
increase activity and increase well-being. We referred people for help with housing and jobs 
but did not routinely focus on how service users could build their assets, meaningfully 
occupy their time and build supportive social networks. Staff were professional and busy but 
they were risk averse and not as optimistic as they could have been about service users’ 
long-term outcomes. Critically, we did not routinely have staff or volunteers in ‘visible 
recovery’, ‘modelling success’ or helping co-deliver services. The audit and subsequent 
process of service change did lead to services becoming more vibrant and co-produced with 
service users and service user-led organisations. It was a journey and process of recovery 
itself. 
 
Implications for OST in Europe: challenges of incorporating harm reduction plus 
reintegration and recovery goals 
Drug policy is rarely evidence based and is frequently politicised. In the United 
Kingdom, a welcome focus on recovery-oriented treatment for DUDs brought an 
unwelcome attempt by politicians to implement a blanket policy to time-limit OST, 
as they incorrectly equated ‘recovery’ with abstinence. Services treating DUDs that 
were seen as ‘successful’ under a previous drug strategy for attracting and retaining 
heroin users in OST were denigrated as ‘failing’ to deliver abstinence outcomes in 
the context of what was perceived as a growing ‘state burden’ of a large number of 
people in OST. This view was challenged and overcome (NTA, 2011; ACMD, 2014), 
reminiscent of some hard-won battles in Europe for the recognition of the legitimacy 
of harm reduction (EMCDDA, 2010). Avoiding a simplistic polarisation of views in 
which abstinence goals are seen as ‘better’ is critical. 
 
Many service users entering OST express aspirations to be drug free ‘one day’, but 
how, when and if they achieve this are moot points. The absence of long-term goals 
may leave people in OST without ambition or hope (although this may enable service 
users, staff and services to avoid ‘failure’). Conversely, having expectations of goal 
achievement can result in service users, staff and policymakers having unrealistic 
expectations of the pace and likelihood of achievement and the level and 
extensiveness of support needed. 
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Our field is hampered by a general lack of research studies on the long-term 
outcomes of the treatment of DUDs in Europe. Although there is some international 
evidence, it would be beneficial to invest in outcome research and avoid setting 
unrealistic performance targets around treatment for DUDs that can create 
perverse, non-evidence-based expectations. 
 
Changing the focus in OST to longer-term outcomes and improving health, well-
being and social functioning can be a challenge to professionals working in OST. It 
may require a change to working methods, with a focus on assets, with optimism 
and in partnership with experts with experience in these services, and with a wider 
range of stakeholders in local systems, including the community and families. 
 
Many countries in the EU have a prematurely aged and ageing opioid-dependent 
population, among whom many are unemployed, have other long-term health 
conditions and are likely to die early. Therefore, achievement of health, well-being 
and integration goals with this group may be challenging, but speaks to our 
obligation to try to achieve parity of quality of life for a marginalised, stigmatised 
and disenfranchised group. 
 
Opportunities 
Opportunities may be created by a re-examination of OST goals and paradigms in the 
EU. 
 
The studies mentioned above indicate that the pattern of OST use is often episodic 
with periods of OST interspersed with periods abstinence or drop-out, followed by 
relapse and return to OST (ACMD, 2014). This pattern of treatment utilisation 
militates against achieving outcomes in all domains. Improving the quality and 
effectiveness of OST is important in all EU Member States. 
 
Implementing local systems for the treatment of opioid use disorders (including OST) 
with an initial focus on reducing harm and preventing opioid overdose deaths, but 
with a focus in OST on recovery and re-integration, could provide multiple benefits. 
It would help to keep people who use opioids alive: they cannot recover if they die. 
This could provide opportunities for service redesign, in partnership with service 
users, to ensure that new models are aspirational, with a focus on improving quality 
of life and meeting wider goals (health, social networks, meaningful activity). 
 
There is potential to develop new system of treatment for DUDs that can harness 
other local services and community assets to help people who use opioids achieve a 
range of recovery outcomes. This may be of particular importance in times of 
economic stress. 
 
The potential role of mutual aid and ‘experts by experience’ may be underutilised in 
some European countries. Involvement with mutual aid increases service users’ 
chances of achieving outcomes that include social connectedness and well-being. 
‘Experts by experience’ working in services that treat DUDs can inspire hope, and 
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‘co-production’ can both enable volunteering and work placements in non-clinical 
posts and enhance service cost-effectiveness. 
 
Re-examining our OST paradigm can provide opportunities to learn from other types 
of healthcare (mental healthcare, managing long-term conditions, other ‘lifestyle 
change’ areas, etc.) and can update definitions and models with new thinking and 
evidence. 
 
Implementing a recovery and re-integration approach may also provide 
opportunities for planners and providers to tackle local stigma and discrimination 
against people who use drugs and promote communities in helping those with drug 
dependence problems re-integrate though promoting visible recovery and positive 
impacts. 
 
Conclusions 
The heterogeneity of people who use drugs and the diversity in severity and 
complexity of drug taking and drug problems in Europe mean that a single goal or 
paradigm such as ‘harm reduction’, ‘recovery’ or ‘abstinence’ is no longer adequate 
to meet the diverse needs we face. 
 
Harm reduction interventions are evidence based, and a harm reduction paradigm of 
goals is suitable for those at risk of harm due to occasional drug use, those who do 
not want to stop using drugs and those who are in treatment for a DUD. Harm 
reduction as an approach is wholly consistent with a public health approach of 
providing responses to acute health needs and is of fundamental importance. 
However, a harm reduction paradigm arguably neglects a longer-term or extensive 
focus on a range of outcome domains required to improve the quality of life of those 
with a long-term chronic health conditions attributable to DUD. 
 
Recovery as a paradigm is focused on those who are dependent on drugs and is 
therefore not appropriate for those who use drugs or those with DUDs who are not 
dependent. A focus on recovery goals alone can lead to a lack of focus on people 
using drugs who are not in treatment for DUDs, on those using drugs occasionally 
but who are still at risk of acute health problems and on the critical interventions 
required to keep people alive (e.g. reduce the risk of opioid overdose deaths). While 
abstinence from drugs is a goal for some people who use drugs, it is not the desired 
goal for some and may not be achievable. 
 
The paradigms of abstinence, harm reduction and recovery alone are therefore 
inadequate frameworks for goals and each brings its own bias and unintended 
negative consequences. 
 
A more nuanced approach to goals for those with DUDs is required. This should 
consider the systems of services required to meet the diverse needs of those with 
DUDs, provide a critical focus on services with goals to reduce the harm related to 
drug taking and (for those with long-term chronic relapsing conditions) should be an 
extensive, holistic approach more akin to long-term health condition management. 
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A more concerted focus on goals to prevent harm and the growing tide of opioid 
overdose deaths is required in many European countries (deaths are more common 
among those not in OST). This may also help ‘futureproof’ services against new 
opioid epidemics such as that caused by fentanyl and the synthetic opioids crisis in 
North America. 
 
A new approach may be of particular importance for the EU’s prematurely ageing 
population of people who use heroin and opioids. For those in OST, medication-
assisted recovery models can provide an ambition to achieve wider health and social 
integration outcomes both for those who need continued OST and those who are 
able to overcome all opioid dependence, without trying to force change in those too 
vulnerable to achieve it. 
 
Europe has led the world in harm reduction. Rather than focusing on old battles and 
a conflict-based approach to paradigms (e.g. harm reduction versus recovery), 
perhaps Europe can lead the way in developing a new integrated paradigm that 
recognises truly integrated systems of services with a range of goals for those with 
DUDs: a new paradigm that incorporates, without bias, a range of interventions and 
goals required to treat DUDs, from prevention of acute harm to management of 
chronic long-term DUDs to enabling people to overcome drug dependence. 
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